18 and older, any sex, with Small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Toxicities Grade 3 or Above Related to TherapyPrimary· Up to 29 months
Measured by the number of adverse of events that are deemed definitely or probably related to the treatments given while receiving study treatment
Group
Value
95% CI
Radiation + Chemo-Immunotherapy
3
Efficacy of Multi-site, Non-ablative Radiation to Standard Systemic Therapy for Patients With Extensive-stage Small Cell Lung, as Measured by a Change in Disease ResponsePrimary· Up to 12 months
Progression free survival at 12 months
Group
Value
95% CI
Radiation + Chemo-Immunotherapy
2
Objective Response Rate, Determined by Disease Response Rate Defined by the RECIST 1.1 CriteriaSecondary· Through study completion (an average of 2 years)
Group
Value
95% CI
Radiation + Chemo-Immunotherapy
5
Overall Survival, Defined as the Time From First Study Treatment to the Time of Death From Any CauseSecondary· Up to 12 months
To determine the percentage of subjects that have achieved survival at the 12 month timepoint
Group
Value
95% CI
Radiation + Chemo-Immunotherapy
4
Pattern of Disease Progression, Defined by the Progression in Radiated Lesions vs. Non-radiated Lesions and the Rates of New Lesions as Determined by RECIST 1.1Secondary· From baseline through progression of disease (approximately 12 months)
Determined by the number of subjects that experienced disease progression in radiated vs. non-radiated lesions and if there were any new lesions
Group
Value
95% CI
Radiation + Chemo-Immunotherapy
1
Radiation + Chemo-Immunotherapy
2
Radiation + Chemo-Immunotherapy
2
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 29 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study is for subjects with untreated Stage IV small cell lung cancer. Subjects will be given radiation therapy for five days, followed by standard of care chemo-immunotherapy (etoposide + carboplatin or cisplatin + durvalumab) for 4 cycles. Subjects may continue to receive durvalumab after 4 cycles have been completed until disease progression.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
NCT04832438 — 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
· Phase 2
· withdrawn
NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
· Phase 2
· not yet recruiting
NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
· Phase 2
· not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive
· Phase 3
· not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa
· Phase 2
· recruiting
Other recruiting trials for Small-cell Lung Cancer
Currently open trials in the same condition.
NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
· Phase 1, PHASE2
· recruiting
NCT07218146 — A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVAT
· Phase 3
· recruiting
NCT07005128 — A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in Fi
· Phase 3
· recruiting
NCT06424067 — Phase 2 Study of Fingolimod in Lung Cancers
· Phase 2
· recruiting
NCT06957314 — A Study of Hospital-at-Home for People Receiving Tarlatamab
· NA
· recruiting
Other Weill Medical College of Cornell University trials
Trials by the same sponsor.
NCT07485712 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2
· NA
· not yet recruiting
NCT05811338 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 1
· NA
· not yet recruiting
NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
· NA
· recruiting
NCT06818734 — Implementation of a Clinical Decision Support Tool for Postpartum Depression
· NA
· not yet recruiting
NCT07485725 — Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 3
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weill Medical College of Cornell University
Last refreshed: 26 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04951115.